Oncimmune Holdings PLC PDMR Dealing (0688J)
April 07 2020 - 5:41AM
UK Regulatory
TIDMONC
RNS Number : 0688J
Oncimmune Holdings PLC
07 April 2020
Oncimmune Holdings plc
("Oncimmune" or the "Company")
PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), a leader in the
development, manufacture and commercialisation of personalised
immunodiagnostics for the screening, detection and care of cancer,
has been notified that Matthew Hall, PDMR and Chief Financial
Officer, has purchased 9,487 ordinary shares of GBP0.01 each in the
Company ("Ordinary Shares") for GBP0.527 per share on 7 April
2020.
Following this transaction, Matthew has a total interest in the
Company of 9,487 Ordinary Shares, representing approximately 0.01
per cent of the Company's issued Ordinary Share capital.
This announcement, including the notification below, is made in
accordance with the requirements of Article 19 of the EU Market
Abuse Regulation.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Matthew Hall
--------------------------------- --------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------------- --------------------------------------
b) Initial Initial notification
notification
/Amendment
--------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
--------------------------------- --------------------------------------
b) LEI 213800HCYIWT6YPI1I02
--------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description Ordinary Shares of GBP0.01 each
of the
financial
instrument,
type
of instrument
Identification ISIN: GB00BYQ94H38
code
b) Nature Purchase of shares
of the
transaction
--------------------------------- --------------------------------------
c) Price(s)
and volume(s)
-------------------- -------------
Price Volume
-------------------- -------------
GBP0.527 9,487
----------------------------------------------------------- -------------
d) Aggregated
information
- Aggregated Same as above
volume
- Price
e) Date 7 April 2020
of the
transaction
--------------------------------- --------------------------------------
f) Place London stock exchange, AIM
of the
transaction
--------------------------------- --------------------------------------
For further information:
Oncimmune Holdings plc
Andrew Stewart, General Counsel and Company Secretary
contact@oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHKKOBQKBKDKQK
(END) Dow Jones Newswires
April 07, 2020 06:41 ET (10:41 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024
